Chromoblastomycosis is a chronic fungal infection of the skin and the subcutaneous tissue caused by traumatic inoculation of a specific group of dematiaceous fungi (usually Fonsecaea pedrosoi, Phialophora verrucosa, Cladosporium carrionii, or Fonsecaea compacta) through the skin.[1]

Several cases of infection by Exophiala species have appeared in the literature.[2] Chromoblastomycosis is classified among the subcutaneous mycoses and is ubiquitous; however, the prevalence is higher in rural populations in countries with a tropical or subtropical climate, such as Madagascar in Africa and Brazil in South America.


Since its identification in the early 1910s, the name of the disease has been frequently misused to encompass other infections caused by dematiaceous fungi. More recently, the advent of immunosuppressive therapies and diseases brought more confusion because of the identification of new agents and clinical settings. With the introduction of the concept of phaeohyphomycosis by McGinnis in 1983,[3] differentiation among these diseases became more obvious. The features of chromoblastomycosis are distinctive enough to consider chromoblastomycosis an independent clinical entity. The infection should not be confused with mycoses, such as mycetoma or phaeohyphomycosis, caused by other dematiaceous fungi.

Nowadays, the term chromoblastomycosis is restricted to the cases in which sclerotic cells are present in tissue. Sclerotic cells, also known as Medlar bodies, are globe-shaped, cigar-colored, thick-walled structures that are 4-12 µm in diameter (see the image below).

View Image

Sclerotic cells on a potassium hydroxide preparation.

Medlar first described them in 1915.[4] These structures multiply by septation, and they induce a purulent and granulomatous inflammatory reaction in tissue (see Histologic Findings).

In 1992,[5] the International Society for Human and Animal Mycology (ISHAM) recommended that the best name to define the disease was chromoblastomycosis, which Terra et al coined in 1922.[6]


Contrary to what appears in some textbooks, chromoblastomycosis was first described by Max Rudolph in 1914 and not by Lane[7] or Medlar[4] in 1915. In 1987, Castro and Castro[8] reported that Max Rudolph, a German physician living in Brazil, published a preliminary communication where the first 6 cases of the disease were described. Rudolph was also able to isolate a dark-colored fungus from 4 of 6 patients; this fungus grew in culture as a dark grey-to-black–colored furlike colony. Rudolph believed this fungus to be a type of blastomycete, and he successfully inoculated the disease in 4 white rats and 2 monkeys. Surprisingly, he did not describe the histologic aspects of the disease or the pathognomonic sclerotic cells, which both Lane and Medlar described 1 year later.

In 1928, Hoffman[9] mentioned that in Cuba in 1908 Guiteras had observed 10 cases of a disease known as chapa in which the clinical aspects resembled those of chromoblastomycosis. Unfortunately, those cases were not published. In 1920, 2 Brazilian physicians, Pedroso and Gomes,[10] published 4 cases that had been under observation for many years, the first one since 1911. According to them, all 4 cases were caused by P verrucosa. Two years later, in 1922, Brumpt[11] concluded that the agents isolated by Pedroso and Gomes could not be classified as Phialophora species, and he coined the denomination Hormodendrum pedrosoi, later renamed F pedrosoi by Negroni[12] in 1936. By 1930, new cases had been described outside the American continent in France, Sumatra, and Poland.[13]

Four different genera are now widely accepted to cause chromoblastomycosis: F pedrosoi, P verrucosa, C carrionii, and F compacta.[14] Rare cases of chromoblastomycosis caused by Rhinocladiella aquaspersa and Exophiala species have also been reported, allowing the inclusion of these species among those that cause the disease.[15, 16, 17, 18, 19]


The infection usually results from a traumatic cutaneous injury that is often not remembered or realized by the patient. The agents often gain entry into the human body by contact with wood splinters or thorns.

The fungi most commonly reported as causing chromoblastomycosis are F pedrosoi, C carrionii, and P verrucosa. A small number of cases due to F compacta, R aquaspersa, and different species of Exophiala have also been reported. In 2007, Chaetomium funicola was identified as a cause of chromoblastomycosis in Panama.[20]

Several authors have demonstrated that a number of different dematiaceous fungi can be isolated from nature. In 1937, Conant[21] demonstrated that a fungus called Cadophora americana, which was isolated from timber, was actually the same organism as P verrucosa. Later isolations were obtained in several countries from materials, such as plants, palm trees, grass, and soil.[18] C carrionii has been isolated from cactaceae, both from the thorns and from the medullae, in Venezuela.[22] C carrionii is the most common agent of chromoblastomycosis in that country, and trauma due to plants is believed to inoculate the skin with the fungus. The fungal cells in human tissue present with the same features as those observed in the inner portions of the plants.

The lesions develop slowly at the site of implantation, producing a warty nodule, which tends to be limited to the skin and the subcutaneous tissue. Over the years, the nodule grows centripetally. In many instances, the central parts of the lesion heal, leaving ivory-colored scars. The disease tends to spread to neighboring healthy skin, forming plaques, which, at times, can involve a whole limb. When nodular lesions predominate over the plaques, the disease assumes a typical cauliflower aspect. Both lymphatic dissemination and cutaneous dissemination have been described.

A new species of Fonsecaea, Fonsecaea nubica, morphologically similar to F pedrosoi and F monophora, has been described in association with chromoblastomycosis.[23] It has described in northern China and in Europe.[24] . Rhinocladiella aquaspersa may also be a causative agent.[25]


The isolation of the causative fungi from nature on several different occasions has added to the demonstration that fungi gain entry into the host's body through traumatic inoculation[1] ; this finding also confirmed that populations at risk are rural workers who walk barefoot in endemic regions where the causative agents are found.

A Brazilian study has suggested a link between the occurrence of lesions on the buttocks and the habit of sitting on babaçu (Orbignya phalerata) shells. The authors have failed to isolate the causative fungus from the shells.[26] In 2004, Salgado et al[27] were able to isolate the same F pedrosoi from a thorny bush (Mimosa pudica) and from a chromoblastomycosis patient. The lesion had developed after an accident at the site where those bushes grew.

On the other hand, in 1994, Zeppenfeldt et al[22] demonstrated that certain cactaceae from the Falcon state in Venezuela had fungi not only on their surfaces and thorns but also in the medulla. Not coincidentally, the fungus was identified as C carrionii, which is the most commonly found organism in chromoblastomycosis cases in that country. The histologic characteristics of the fungus in plant tissue resembled that found in humans. Experimental inoculation of C carrionii in goats, performed n Venezuela, demonstrated that although chromoblastomycosis affecting that genus of mammals has never been reported, C carrionii caused cellular reactions in goats identical to those seen in humans at the first stages of infection.[28]

In 1989, Tsuneto et al[29] demonstrated a higher frequency of HLA-A29 in patients with chromoblastomycosis; this finding suggests that genetics might have an influence in the acquisition of the disease.



The disease has been described worldwide, but the incidence is greater in tropical and subtropical regions located between 30° N and 30° S.[30]

An estimated 20% of cases are found in temperate climates, such as in Japan,[31] Canada,[32] Finland,[33, 34] and Romania and the Czech Republic.[13] Chromoblastomycosis most commonly affects male agricultural workers in rural regions of North America, Central America, and South America, but chromoblastomycosis does occur worldwide, including Europe, England, India, South Africa, and Australia. The highest incidence of chromoblastomycosis in the world is in the African country of Madagascar, and a large number of cases have been reported in Japan. A survey in the Brazilian Amazon disclosed an extremely high incidence of chromoblastomycosis (1.6 cases per 10,000 population) in a village called Monte Negro, in the state of Rondonia.

Thirty cases from the Republic of China between 2003 and 2016 were evaluated; patients were predominately male (2.75:1) with a mean age of onset of 65.9 years. Disease duration ranged from 2 months to 20 years.[35]

Countries with the highest number of cases are Madagascar and Brazil. Several different African and Latin American countries, such as Gabon, Colombia, Venezuela, Cuba, the Dominican Republic, and Mexico, also have high prevalence rates.

F pedrosoi infection is most commonly observed in humid climates, whereas C carrionii infection is normally found in dry areas.

Farming is the most common occupation in patients with chromoblastomycosis.[36]

Fonsecaea monophora is the predominant etiologic agent of chromoblastomycosis in southern China.[37]

Chromoblastomycosis in central Kerala, India, was found to be more common among male agriculturists than others. The most common etiologic species isolated was F pedrosoi.[38]


No racial predilection is usually noted. In one Brazilian study in São Paulo State, chromoblastomycosis was evident most in white male rural workers, who averaged age 60 years.[39]


Most series reports indicate a clear male predominance, although a small number of reports describe similar male-to-female ratios. Approximately 70% of cases are seen in men. The explanation for this male predominance is not clear, but men are assumed to be more commonly involved in agricultural work and are more prone to inflict injuries on themselves, thereby causing self-inoculation, rather than women who are supposedly more dedicated to house jobs.

The possible inhibitory effect of female hormones on the growth of fungi may partially explain the relatively low number of cases in females.


Patients with the disease are most commonly aged 30-50 years. The period between inoculation and disease development is believed to last years, explaining the scarcity of children with chromoblastomycosis. The disease is rarely found in children exposed to the same environmental conditions as adults.


The prognosis for chromoblastomycosis tends to be good, especially for small and localized lesions. When the affected area is large, as in severe cases, cure is difficult, although control is easily achieved. Cicatricial and unaesthetic scars are the rule after the disease is eliminated.

Success in a specialized Brazilian center with clinical care, laboratory support, and pharmaceutical care was noted in 18 cases, with a cure rate of 80%.

Mortality due to chromoblastomycosis is a rare event.

Morbidity relates directly to the severity of the disease. Initially, in the papule or nodule phase, the disease is asymptomatic. When the nodules coalesce, forming large plaques and sometimes involving the whole limb, complications may appear. Common complications include ulceration, lymphedema, and secondary infection.

Fungal causes of chromoblastomycosis are becoming more frequent opportunistic pathogens in solid organ transplant recipients, producing significant morbidity.[40]


Patients usually do not report discomfort, and they tend to not seek medical care until secondary infection or elephantiasis ensues.

Physical Examination

The disease appears at the site of a previous often unnoticed or unremembered trauma to the skin. After several years, a small, raised, erythematous, asymptomatic papule develops. As the chromoblastomycosis lesion develops over years, it assumes a scaly and infiltrated aspect, generally leading to either of the two most common clinical variants: nodular or plaque. In both types, the surface is verrucous, and lesions spread laterally to contiguous healthy tissue. Note the images below.

View Image

Chromoblastomycosis, tumoral form. Chronic disease led to elephantiasis and involvement of the entire lower limb.

View Image

Plaque lesion on the foot. The verrucous aspect of the lesion differentiates it from other infectious dermatoses that may present as a verrucous lesio....

In general, the disease remains localized to the area of the initial infection or neighboring skin, but lymphatic and hematogenous dissemination may occur, producing metastatic lesions away from the primary site. The nodular type of lesion normally develops into verrucous, pedunculated, cauliflowerlike florets, while the plaque type spreads peripherally, with an active, raised border, leaving a central healed area with atrophic and yellowish scar tissue.

On the surface of both types of clinical variants, numerous black dots may be observed where the causative organisms are preferentially found. Hemopurulent material covering small ulcerations is commonly observed.

Cutaneous localized annular chromoblastomycosis has been described as well-circumscribed, slow-growing, annular, papulosquamous or papulosquamous-verrucous patches or plaques with no regression despite the use of topical antifungals.[41] These plaques may be atrophic.[42]

Secondary infection with bacteria is common, giving the lesion a characteristic ill odor. Secondary infection is believed to be important in the genesis of lymph stasis and consequently of elephantiasis. In old cases, lesions in different stages of development can be found. Extracutaneous spread may occur rarely, due to hematogenic and lymphatic dissemination. Contiguous spread to the underlying bone may produce an osteolytic lesion.[43]

The sites most commonly affected are the lower extremities, especially the feet. The hands, the arms, and the buttocks are also frequently involved, and sporadic reports mention lesions on the ears, face,  breasts, and axillae.[44]

Auricular chromoblastomycosis due to Fonsecaea pedrosoi, the most common agent found in Brazil, has been described.[45]

Morphological variants occur. Rarely, chromoblastomycosis may resemble sporotrichosis with verrucous nodules and a lymphatic distribution on the forearm expanding into verrucous plaques.[25] Chromoblastomycosis may also be evident as a large cauliflowerlike mass.[46]

Although it is most often evident ranging from a small ulcer, plaques, papulonodular lesions, or cauliflowerlike warty masses and cicatricial forms, it may rarely appear as a phagedenic ulcer on the face.[47] The dermatoscopic features can be variable, with red dots, white vague areas, black globules, and sandlike patterns sometimes evident.[35]


The most common complications of chromoblastomycosis are ulceration, secondary bacterial infection, lymphedema that leads to elephantiasis, and myiasis.[48]

Leech bites may predispose to bacterial infection.

Rare cases of malignant transformation (squamous cell carcinoma) of chromoblastomycosis have been documented.[49]  

Cutaneous chromoblastomycosis with dissemination to brain has been described.[50]

Exophiala dermatitidis disseminated infection has been described as producing a fatal infection in an allogenic hematopoietic stem cell transplant recipient.[51]

Laboratory Studies

Among the possible laboratory tests to be obtained, direct examination of 10% potassium hydroxide cleared lesion scrapings is by far the most useful. Typical, thick-walled, cigar-colored, sclerotic cells, also known as Medlar bodies, are readily seen, sometimes more colorfully referred to as golden-brown septate “copper pennies.”[57] Although these cells are pathognomonic of chromoblastomycosis, they do not give specific information on the agent. Eventually, dematiaceous hyphae can also be observed. Identifying the agent is easier when the specimens collected include the black dots present in the lesions. In 2005, Miranda et al[58] suggested the use of vinyl adhesive tape for collecting and identifying some types of deep-seated mycoses in which the infectious agents can be observed in the horny layer of the epidermis in transepidermal elimination events. Many fungal microorganisms in a scaly crust may be documented histologically following intralesional corticosteroids in patients with chromoblastomycosis.[59] Note the image below.

View Image

Sclerotic cells on a potassium hydroxide preparation.

In culture, each causative agent produces a similar pattern, that of a slow-growing, dark, velvety colony with a black obverse. Identification of individual species is handled in the usual manner by observing various characteristics, including conidia production. Note the image below.

View Image

Micromorphology of Cladosporium carrionii (left) and Fonsecaea pedrosoi (right), the 2 most commonly isolated agents in chromoblastomycosis.

Serologic tests are exclusively used for research matters, and they are not routinely used or available. A recently isolated, highly specific and sensitive immunoblotting method depicted a 54-kd antigen from F pedrosoi[60] that may prove to be helpful in the study of the disease. Note the image below.

View Image

Culture of Fonsecaea pedrosoi on Sabouraud agar. The black velvety colony has the same macroscopic appearance as the colonies of other chromoblastomyc....

An enzyme-linked immunosorbent assay (ELISA) using a somatic antigen of C carrionii was tested to serologically follow cases of chromoblastomycosis due to C carrionii before, during, and after therapy. ELISA proved to be a valuable tool for the diagnosis and follow-up of patients with chromomycosis (due to C carrionii). According to the authors[61] in 2005, the use of an ELISA might be useful to establish remission criteria in chromoblastomycosis caused by C carrionii.

Duplex polymerase chain reaction is a rapid and specific assay for identification of Fonsecaea isolates, mainly for the strains that are difficult to identify using morphologic methods.[62]

A rapid and sensitive assay for identification of pathogenic species of Fonsecaea without sequencing can be obtained using rolling circle amplification (RCA). This simple, sensitive, and low-cost method may prove practical.[63]

Imaging Studies

Bone involvement is not a typical finding in chromoblastomycosis. Long-lasting lesions may lead indirectly to bone changes, making it necessary to evaluate possible bone compromise with regular radiography, especially when lesions are old, located at sites with scarce subcutaneous tissue, or associated with lymphedema.

Lymphoscintigraphy has been used to evaluate lymphedema, but it is not routinely used.[64]

Histologic Findings

In cutaneous lesions, the cigar-colored fungi are easily seen in hematoxylin and eosin–stained sections. No special stains are needed. The typical finding is a pseudoepitheliomatous hyperplasia of the epidermis with a diffuse, lymphomononuclear inflammatory infiltrate in the dermis. The tissue response to the fungus is typically mixed.

True and pure abscesses or microabscesses, granulomas, granulomatous reactions, and abscesses surrounded by a granulomatous reaction with giant cells may be seen in the same section.[65] Inside the giant cells, brown-colored, thick-walled fungal cells may be seen. These muriform fungal cells may be single, 2-celled, or multiple-celled; this feature is a result of multiplication by septation rather than budding. Note the image below.

View Image

Hematoxylin and eosin–stained section shows typical sclerotic cells inside an abscess. Sclerotic cells present as round, thick-walled, cigar-colored s....

Transepidermal elimination of the fungal cells is the histologic counterpart of the black dots clinically evident in chromoblastomycosis lesions. An unusual dermal response has been described by Jawitz et al[66] in 2007, consisting of dermal effacement by a spindle cell proliferation arranged in sweeping fascicles.


Staging of the disease is especially useful for academic matters. Because treatment is still difficult, several papers in the literature describe the results obtained with different therapeutic methods. Unfortunately, most papers are single case reports, and follow-up tends to be short. The lack of uniformity in staging contributes to the low reproducibility of the proposed regimens.

In 1999, Castro devised an elegant, clinically based, physician friendly index to stage chromoblastomycosis. The severity index is based on the extension of the diseased area, the number of lesions, the presence of complications (eg, lymphedema, ulceration, secondary infection), and the unresponsiveness to previous treatments. According to this scoring system, patients are classified as having mild (up to 3 points), moderate (4-6 points), or severe (7-10 points) disease.

A scoring system for staging chromoblastomycosis is as follows:

Approach Considerations

One of the most characteristic features of chromoblastomycosis is its refractoriness to treatment. Treatment options include oral itraconazole (as monotherapy or with oral 5-flucytosine [5-FC]), locally applied heat therapy, cryosurgery, photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) irradiation, and combination therapy.[67] Successful treatment of severe chromoblastomycosis with itraconazole and 5-FC association has been reported.[68] Therapeutic success is related to the causative agent, as well as the clinical form and severity of the chromoblastomycosis.

Medical Care

Several authors indicate itraconazole as the best choice of therapy.[18, 69, 70] Daily doses range from 200-400 mg, and results vary greatly. Adverse effects are not common, but efficacy is not as high as one would desire. Severe cases should be treated for several years. The authors' experience in treating more than 25 patients with varying degrees of severity for as long as 5 years shows that itraconazole produces dramatic improvement after a few months of therapy; however, a complete cure is rarely reached, especially in severe cases. These results might be because of the predominantly fungistatic mechanism of action of the drug. In numerous cases, drug withdrawal led to relapse.

Overall results of the various treatments in one Mexican study were as follows: 31% of the conditions were cured, 57% improved, and 12% did not respond to treatment. Optimal results were obtained with cryosurgery for small lesions; itraconazole for large ones; and, in some cases, the combination of both.[71] Combination therapy with itraconazole and terbinafine during the early stages of treatment of chromoblastomycosis caused by F monophora has been suggested.[72]  Another report noted this combination can be effective.[73]

Although few studies have been published, the association of itraconazole and 5-FC is promising.[74] As with 5-FC and amphotericin B, itraconazole and 5-FC produce a synergistic effect. Multidrug therapy for chromoblastomycosis seems to be an interesting approach and may also be used with cryosurgery.

In 1996, Esterre et al[75] presented interesting results when using terbinafine to treat more than 100 patients in Madagascar. Similar to that of itraconazole, the drug presented below optimal results, it is exceedingly expensive, and treatment lasts several months. To date, no reports on the association of terbinafine and itraconazole or terbinafine and 5-FC have appeared in the literature.

Posaconazole (Noxafil), a new triazole derivative, has been experimentally used to treat chromoblastomycosis. Posaconazole has received approval from the US Food and Drug Administration for prophylaxis against invasive Aspergillus and Candida infections in patients at high risk because of severe immunosuppression. The results of isolated cases suggest that outcomes may be slightly superior to those obtained by itraconazole or terbinafine (Unpublished data on file, Dr. Shikanai-Yasuda, Department of Infectious Diseases, Univ. São Paulo). According to Keating[76] in 2005, posaconazole at 800 mg/d was associated with an overall success rate of 82% in persons with refractory chromoblastomycosis.

There is a case report of one application of topical imiquimod being beneficial.[77]

Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) irradiation may be adjunctive, in combination with antifungal medication.[78]  PDT can be combined with terbinafine.[79]  Positive clinical improvement was obtained when voriconazole at 200 mg was combined with terbinafine at 250 mg in treating one patient with refractory chromoblastomycosis.[80] Successful treatment using ALA-PDT has been described in a patient with leukopenia.[81]  

Heat therapy is another treatment. The use of pocket warmers has proven successful in the treatment of a limited number of cases. Apparently, an increase in skin temperature somehow impairs fungal development.[82]  It may take as long as 6 months or more.[83]

As there is no standard treatment and high rates of relapse, topical imiquimod has been used with substantial improvement documented both with and without concurrent oral antifungal therapy.[84]

Lymphedema and secondary infection or ulcerated lesions are common complications of chromoblastomycosis on the lower limbs. Physiotherapy and lymphatic drainage are useful in preventing lymphedema. Ulcers and secondary infection are dealt with by appropriate nursing care. Oral antibiotics may be used.

Surgical Care

Cryosurgery with liquid nitrogen can be used to treat chromoblastomycosis, especially localized lesions. Several reports have appeared in the literature showing that the method has been used on almost every continent with good results. Combination therapy with cryotherapy and terbinafine has been advocated.[85]  Freezing time in one study varied from 30 seconds to 4 minutes, and the number of cycles varied from 1 to more than 40. All localized lesions responded extremely well to treatment, with no relapse for as long as 15 years, a follow-up period unparalleled in the literature. Three patients with generalized lesions attained clinical and mycologic remission for as long as 26 months, and 3 had significant improvement without cure.[86]

Multiple treatment modalities are often combined, such as long courses of antifungals, surgical excision, and destructive physical therapies, because chromoblastomycosis is one of the most difficult deep mycotic infections to eradicate.[87] Final treatment with surgical excision may be beneficial.[88]

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Itraconazole (Sporanox)

Clinical Context:  Itraconazole has fungistatic activity. It is a synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P450–dependent synthesis of ergosterol, a vital component of fungal cell membranes. Results may take several weeks to be noted, and treatment may last several months or years.

Terbinafine (Lamisil)

Clinical Context:  Terbinafine is a member of allylamine family and is believed to be a fungicidal agent. It inhibits ergosterol synthesis via squalene epoxidase, resulting in decreased ergosterol levels and increased concentrations of squalene.

Flucytosine (Ancobon)

Clinical Context:  5-FC has proven useful when used in association with oral itraconazole. It should not be used as monotherapy.

Class Summary

The mechanism of action usually involves inhibiting pathways (eg, enzymes, substrates, transport) necessary for sterol/cell membrane synthesis or altering the permeability of the cell membrane (polyenes) of the fungal cell.


Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; I serve on a safety monitoring committee for Principia Biopharma for: Allergen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.


Eugeniusz Baran, MD, PhD Professor, Department of Dermatology, Venereology and Allergology, Head, Clinic of Dermatology and Venereology, Wroclaw Medical University, Poland

Eugeniusz Baran, MD, PhD is a member of the following medical societies: European Confederation of Medical Mycology and International Society for Human and Animal Mycology

Disclosure: Nothing to disclose.

Luiz Guilherme M Castro, MD Supervising Physician, Master and Doctor in Dermatology, Division of Dermatology, Hospital Das Clinicas, University of São Paulo, Brazil

Luiz Guilherme M Castro is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.


  1. Rubin HA, Bruce S, Rosen T, McBride ME. Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis. J Am Acad Dermatol. 1991 Nov. 25(5 Pt 2):951-4. [View Abstract]
  2. Castro LG, Pimentel ER, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int J Dermatol. 2003 May. 42(5):408-12. [View Abstract]
  3. McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983 Jan. 8(1):1-16. [View Abstract]
  4. Medlar EM. A cutaneous infection caused by a new fungus Phialophora verrucosa with a study of the fungus. J Med Res. 1915. 32:507-22.
  5. Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol. 1992. 30(1):1-10. [View Abstract]
  6. Terra F, Torres M, Fonseca Filho O. Novo tipo de dermatite verrucosa; micose por Acrotheca com associado de leishmaniose. Brasil Medico. 1922. 36:363-8.
  7. Lane CG. A cutaneous disease caused by a new fungus Phialophora verrucosa. J Cutan Dis. 1915. 33:840-6.
  8. Castro RM, Castro LG. On the priority of description of chromomycosis. Mykosen. 1987 Sep. 30(9):397-403. [View Abstract]
  9. Hoffman WH. Die Chromoblastomykose in Kuba. Arch Schiffs u Tropen Hyg. 1928. 32:485-7.
  10. Pedroso A, Gomes JM. 4 casos de dermatite verrucosa produzida pela Phialophora verrucosa. Ann Paulistas de Medicina e Cirurgia. 1920. 11:53-61.
  11. Brumpt E. Prés de Parasitologie. 3rd ed. Paris, France: Masson; 1922. 1105.
  12. Negroni R. Estudio del primer caso argentino de cromomicosis, Fonsecaea (Negroni) pedrosoi (Brumpt) 1921. Rev Inst Bacteriol. 1936. 7:419-26.
  13. Rippon JW. Chromoblastomycosis and related dermal infections caused by dematiaceous fungi. Medical Mycology. The Pathogenic Fungi and the Pathogenic Actinomycetes. 2nd ed. Philadelphia, Pa: WB Saunders; 1982. 249-76.
  14. Lacaz CS, Porto E, Martins JEC. Fungos, actinomicetos e algas de interesse medico. Micologia Medica. 8th ed. Sao Paulo, Brazil: Sarvier; 1991. 373-86.
  15. South DA, Brass C, Stevens DA. Chromohyphomycosis. Treatment wit ketoconazole. Arch Dermatol. 1981 May. 117(5):311-2. [View Abstract]
  16. Naka W, Harada T, Nishikawa T, Fukushiro R. A case of chromoblastomycosis: with special reference to the mycology of the isolated Exophiala jeanselmei. Mykosen. 1986 Oct. 29(10):445-52. [View Abstract]
  17. Barba-Gomez JF, Mayorga J, McGinnis MR, Gonzalez-Mendoza A. Chromoblastomycosis caused by Exophiala spinifera. J Am Acad Dermatol. 1992 Feb. 26(2 Pt 2):367-70. [View Abstract]
  18. Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992 Nov. 31(11):805-12. [View Abstract]
  19. Padhye AA, Hampton AA, Hampton MT, Hutton NW, Prevost-Smith E, Davis MS. Chromoblastomycosis caused by Exophiala spinifera. Clin Infect Dis. 1996 Feb. 22(2):331-5. [View Abstract]
  20. Piepenbring M, Caceres Mendez OA, Espino Espinoza AA, Kirschner R, Schofer H. Chromoblastomycosis caused by Chaetomium funicola: a case report from Western Panama. Br J Dermatol. 2007 Nov. 157(5):1025-9. [View Abstract]
  21. Conant NF. The occurrence of a human pathogenic fungus as a saprophyte in nature. Mycologia. 1937. 29:597-8.
  22. Zeppenfeldt G, Richard-Yegres N, Yegres F. Cladosporium carrionii: hongo dimorfico en cactaceas de la zona endemica para la cromomicosis en Venezuela. Rev Iberoam Micol. 1994. 11:61-3.
  23. Najafzadeh MJ, Sun J, Vicente V, Xi L, van den Ende AH, de Hoog GS. Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol. 2010 Mar 22. [View Abstract]
  24. You Z, Yang X, Yu J, Zhang J, Ran Y. Chromoblastomycosis Caused by Fonsecaea nubica: First Report in Northern China and Literature Review. Mycopathologia. 2019 Feb. 184 (1):97-105. [View Abstract]
  25. Badali H, Bonifaz A, Barrón-Tapia T, Vázquez-González D, Estrada-Aguilar L, Cavalcante Oliveira NM, et al. Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol. 2010 Jan 29. [View Abstract]
  26. Silva CM, da Rocha RM, Moreno JS, et al. [The coconut babaçu (Orbignya phalerata martins) as a probable risk of human infection by the agent of chromoblastomycosis in the State of Maranhão, Brazil]. Rev Soc Bras Med Trop. 1995 Jan-Mar. 28(1):49-52. [View Abstract]
  27. Salgado CG, da Silva JP, Diniz JA, et al. Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2004 Jan-Feb. 46(1):33-6. [View Abstract]
  28. Martinez EC, Rey Valeiron C, Yegres F, Reyes R. [The goat: approach to an animal model in human chromomycosis]. Invest Clin. 2005 Jun. 46(2):131-8. [View Abstract]
  29. Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol. 1989. 27(3):181-5. [View Abstract]
  30. Brygoo ER, Destombes P. Epidemiologie de la chromoblastomycose humaine. Bull Inst Pasteur. 1975. 74:219-43.
  31. Nishimoto K. Chromomycosis in Japan. Ann Soc Belg Med Trop. 1981 Sep. 61(3):405-12. [View Abstract]
  32. Berger L, Langeron M. Sur un type noveau de chromomycose observé au Canada (Torula bergeri n. sp). Ann Parasit Hum Comp. 1949. 24:574-99.
  33. Putkonen T. [Chromomycosis in Finland. The possible role of the Finnish sauna in its spreading]. Hautarzt. 1966 Nov. 17(11):507-9. [View Abstract]
  34. Sonck CE. Chromomycosis in Finland. Dermatology. 1975. 19:189-93.
  35. Yang CS, Chen CB, Lee YY, Yang CH, Chang YC, Chung WH, et al. Chromoblastomycosis in Taiwan: A report of 30 cases and a review of the literature. Med Mycol. 2018 Jun 1. 56 (4):395-405. [View Abstract]
  36. Pradhan SV, Talwar OP, Ghosh A, Swami RM, Shiva Raj KC, Gupta S. Chromoblastomycosis in Nepal: a study of 13 cases. Indian J Dermatol Venereol Leprol. 2007 May-Jun. 73(3):176-8. [View Abstract]
  37. Xi L, Sun J, Lu C, et al. Molecular diversity of Fonsecaea (Chaetothyriales) causing chromoblastomycosis in southern China. Med Mycol. 2009 Feb. 47(1):27-33. [View Abstract]
  38. Chandran V, Sadanandan SM, Sobhanakumari K. Chromoblastomycosis in kerala, India. Indian J Dermatol Venereol Leprol. 2012 Nov-Dec. 78(6):728-33. [View Abstract]
  39. Marques GF, Masuda PY, Sousa JM, Barreto JA, Wachholz PA. Clinical and demographic profile of chromoblastomycosis in a referral service in the midwest of São Paulo state (Brazil). An Bras Dermatol. 2015 Jan-Feb. 90(1):140-2. [View Abstract]
  40. Schieffelin JS, Garcia-Diaz JB, Loss GE Jr, Beckman EN, Keller RA, Staffeld-Coit C, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis. 2014 Mar 17. [View Abstract]
  41. Salgado CG, da Silva MB, Yamano SS, Salgado UI, Diniz JA, da Silva JP. Cutaneous localized annular chromoblastomycosis. J Cutan Pathol. 2009 Feb. 36(2):257-61. [View Abstract]
  42. El Euch D, Mokni M, Haouet S, Trojjet S, Zitouna M, Ben Osman A. [Erythemato-squamous papular and atrophic plaque on abdomen: chromoblastomycosis due to Fonsecaea pedrosoi]. Med Trop (Mars). 2010 Feb. 70(1):81-3. [View Abstract]
  43. Sharma NL, Sharma VC, Mahajan V, Shanker V, Sarin S. Chromoblastomycosis with underlying osteolytic lesion. Mycoses. 2007 Nov. 50(6):517-9. [View Abstract]
  44. Krishna S, Shenoy MM, Pinto M, Saxena V. Two cases of axillary chromoblastomycosis. Indian J Dermatol Venereol Leprol. 2016 Jan 21. [View Abstract]
  45. França K, Villa RT, de Azevedo Bastos VR, Almeida AC, Massucatti K, Fukumaru D, et al. Auricular Chromoblastomycosis: A Case Report and Review of Published Literature. Mycopathologia. 2011 Feb 17. [View Abstract]
  46. Sharma A, Hazarika NK, Gupta D. Chromoblastomycosis in Sub-Tropical Regions of India. Mycopathologia. 2010 Jan 22. [View Abstract]
  47. Naveen KN, Naik AS, Shetty PC, Pai VV, Hanumanthayya K, Udupishastry D. Chromoblastomycosis presenting as a phagedenic ulcer on the face. Int J Dermatol. 2011 Sep 19. [View Abstract]
  48. Slesak G, Inthalad S, Strobel M, Marschal M, Hall M Jr, Newton PN. Chromoblastomycosis after a leech bite complicated by myiasis: a case report. BMC Infect Dis. 2011 Jan 12. 11:14. [View Abstract]
  49. Rojas OC, González GM, Moreno-Treviño M, Salas-Alanis J. Chromoblastomycosis by Cladophialophora carrionii Associated with Squamous Cell Carcinoma and Review of Published Reports. Mycopathologia. 2015 Feb. 179(1-2):153-7. [View Abstract]
  50. Thomas E, Bertolotti A, Barreau A, Klisnick J, Tournebize P, Borgherini G, et al. From phaeohyphomycosis to disseminated chromoblastomycosis: A retrospective study of infections caused by dematiaceous fungi. Med Mal Infect. 2018 Jun. 48 (4):278-285. [View Abstract]
  51. Hagiya H, Maeda T, Kusakabe S, Kawasaki K, Hori Y, Kimura K, et al. A fatal case of Exophiala dermatitidis disseminated infection in an allogenic hematopoietic stem cell transplant recipient during micafungin therapy. J Infect Chemother. 2019 Jun. 25 (6):463-466. [View Abstract]
  52. Verma S, Verma GK, Singh G, Kanga A, Sharma V, Gautam N. Facial chromoblastomycosis in sub-Himalayan region misdiagnosed as cutaneous leishmaniasis: brief report and review of Indian literature. Dermatol Online J. 2012 Oct 15. 18(10):3. [View Abstract]
  53. Azevedo CM, Marques SG, Santos DW, Silva RR, Silva NF, Santos DA, et al. Squamous Cell Carcinoma Derived From Chronic Chromoblastomycosis in Brazil. Clin Infect Dis. 2015 Feb 13. [View Abstract]
  54. Campolina SS, Caligiorne RB, Rezende-Silva S, Hahn RC, De Hoog GS. A skin infection mimicking chromoblastomycosis by a Capnodialean fungus. Med Mycol. 2009 Feb. 47(1):81-5. [View Abstract]
  55. Bui AQ, Espana EM, Margo CE. Chromoblastomycosis of the conjunctiva mimicking melanoma of the ciliary body. Arch Ophthalmol. 2012 Dec 1. 130(12):1615-7. [View Abstract]
  56. Skupsky H, Junkins-Hopkins J. Counterfeit Pennies: Distinguishing Chromoblastomycosis From Phaeohyphomycotic Infections. Am J Dermatopathol. 2017 Jun. 39 (6):485-487. [View Abstract]
  57. Anjaneyan G, Jagadeesan S, Thomas J. Cytodiagnostic copper pennies in chromoblastomycosis. Indian Dermatol Online J. 2016 Mar-Apr. 7 (2):145-6. [View Abstract]
  58. Miranda MF, Silva AJ. Vinyl adhesive tape also effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidioidomycosis. Diagn Microbiol Infect Dis. 2005 May. 52(1):39-43. [View Abstract]
  59. Saxena AK, Jain S, Ramesh V, Singh A, Capoor MR. Chromoblastomycosis: Demonstration of abundant microorganisms on microscopy of a scaly crust following intralesional corticosteroids. J Eur Acad Dermatol Venereol. 2014 Feb 14. [View Abstract]
  60. Vidal MS. Estudo imunoquimco de um antigeno de Fonsecaea pedrosoi e padronizao de teiicas sorologicas para cromoblastomicose causada por este fungo. Sao Paulo, Brazil: University of Sao Paulo; 2002.
  61. Oberto-Perdigon L, Romero H, Perez-Blanco M, Apitz-Castro R. [An ELISA test for the study of the therapeutic evolution of chromoblastomycosis by Cladophialophora carrionii in the endemic area of Falcon State, Venezuela]. Rev Iberoam Micol. 2005 Mar. 22(1):39-43. [View Abstract]
  62. de Andrade TS, Cury AE, de Castro LG, Hirata MH, Hirata RD. Rapid identification of Fonsecaea by duplex polymerase chain reaction in isolates from patients with chromoblastomycosis. Diagn Microbiol Infect Dis. 2007 Mar. 57(3):267-72. [View Abstract]
  63. Najafzadeh MJ, Sun J, Vicente VA, de Hoog GS. Rapid identification of fungal pathogens by rolling circle amplification using Fonsecaea as a model. Mycoses. 2011 Sep. 54(5):e577-82. [View Abstract]
  64. Ogawa MM. Cromoblastomicose: Teraplicas e alternativos linfocintilograpicas. Sao Paulo, Brazil: Tese de Mestrado, Escola Paulista de Medicina; 2001.
  65. Salfelder K, de Liscano TR, Sauerteig E. Atlas of Fungal Pathology. Kluwer/Dordrecht; 1990. 145-50.
  66. Jawitz RS, Calder KB, Turner LM, Schlauder S, Morgan MB. Cryptic "chromo-fibroma". Am J Dermatopathol. 2007 Dec. 29(6):573-5. [View Abstract]
  67. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009 Feb. 47(1):3-15. [View Abstract]
  68. Antonello VS, Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo. 2010 Dec. 52(6):329-31. [View Abstract]
  69. Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988. 544:504-16. [View Abstract]
  70. Graybill JR. Future directions of antifungal chemotherapy. Clin Infect Dis. 1992 Mar. 14 Suppl 1:S170-81. [View Abstract]
  71. Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001. 44(1-2):1-7. [View Abstract]
  72. Zhang J, Xi L, Lu C, et al. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses. 2009 Mar. 52(2):176-81. [View Abstract]
  73. Shen XC, Dai XN, Xie ZM, Li P, Lu S, Li JH, et al. A Case of Chromoblastomycosis Caused by Fonsecaea pedrosoi Successfully Treated by Oral Itraconazole Together with Terbinafine. Dermatol Ther (Heidelb). 2020 Apr. 10 (2):321-327. [View Abstract]
  74. Pradinaud R, Bolzinger T. Treatment of chromoblastomycosis. J Am Acad Dermatol. 1991 Nov. 25(5 Pt 1):869-70. [View Abstract]
  75. Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996 Jun. 134 Suppl 46:33-6; discussion 40. [View Abstract]
  76. Keating GM. Posaconazole. Drugs. 2005. 65(11):1553-67; discussion 1568-9. [View Abstract]
  77. Belda W Jr, Criado PR, Passero LFD. Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod. J Dermatol. 2020 Apr. 47 (4):409-412. [View Abstract]
  78. Lyon JP, Pedroso e Silva Azevedo Cde M, Moreira LM, de Lima CJ, de Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia. 2011 Oct. 172(4):293-7. [View Abstract]
  79. Hu Y, Huang X, Lu S, Hamblin MR, Mylonakis E, Zhang J, et al. Photodynamic Therapy Combined with Terbinafine Against Chromoblastomycosis and the Effect of PDT on Fonsecaea monophora In Vitro. Mycopathologia. 2015 Feb. 179(1-2):103-9. [View Abstract]
  80. Yang Y, Hu Y, Zhang J, Li X, Lu C, Liang Y, et al. A refractory case of chromoblastomycosis due to Fonsecaea monophora with improvement by photodynamic therapy. Med Mycol. 2012 Feb 7. [View Abstract]
  81. Huang X, Han K, Wang L, Peng X, Zeng K, Li L. Successful treatment of chromoblastomycosis using ALA-PDT in a patient with leukopenia. Photodiagnosis Photodyn Ther. 2019 Feb 12. [View Abstract]
  82. Kinbara T, Fukushiro R, Eryu Y. Chromomycosis--report of two cases successfully treated with local heat therapy. Mykosen. 1982 Dec. 25(12):689-94. [View Abstract]
  83. Tagami H, Ginoza M, Imaizumi S, Urano-Suehisa S. Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol. 1984 Apr. 10(4):615-9. [View Abstract]
  84. da Glória Teixeira de Sousa M, Júnior WB, Spina R, Lota PR, Valente NS, Brown GD, et al. Topical application of Imiquimod as a treatment for Chromoblastomycosis. Clin Infect Dis. 2014 Mar 14. [View Abstract]
  85. Bassas-Vila J, Fuente MJ, Guinovart R, Ferrándiz C. Chromoblastomycosis: response to combination therapy with cryotherapy and terbinafine. Actas Dermosifiliogr. 2014 Mar. 105(2):196-8. [View Abstract]
  86. Pimentel ER, Castro LG, Cuce LC, Sampaio SA. Treatment of chromomycosis by cryosurgery with liquid nitrogen: a report on eleven cases. J Dermatol Surg Oncol. 1989 Jan. 15(1):72-7. [View Abstract]
  87. Ameen M. Managing chromoblastomycosis. Trop Doct. 2010 Apr. 40(2):65-7. [View Abstract]
  88. Badali H, Fernández-González M, Mousavi B, Illnait-Zaragozi MT, González-Rodríguez JC, de Hoog GS, et al. Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba. Mycopathologia. 2013 Mar 8. [View Abstract]

Sclerotic cells on a potassium hydroxide preparation.

Chromoblastomycosis, tumoral form. Chronic disease led to elephantiasis and involvement of the entire lower limb.

Plaque lesion on the foot. The verrucous aspect of the lesion differentiates it from other infectious dermatoses that may present as a verrucous lesion, namely, cutaneous leishmaniasis, sporotrichosis, cutaneous tuberculosis, and cutaneous mycobacteriosis.

Sclerotic cells on a potassium hydroxide preparation.

Micromorphology of Cladosporium carrionii (left) and Fonsecaea pedrosoi (right), the 2 most commonly isolated agents in chromoblastomycosis.

Culture of Fonsecaea pedrosoi on Sabouraud agar. The black velvety colony has the same macroscopic appearance as the colonies of other chromoblastomycosis-causing agents (eg, Cladosporium carrionii, Fonsecaea compacta, Phialophora verrucosa, Rhinocladiella aquaspersa, Exophiala species).

Hematoxylin and eosin–stained section shows typical sclerotic cells inside an abscess. Sclerotic cells present as round, thick-walled, cigar-colored structures.

Sclerotic cells on a potassium hydroxide preparation.

Micromorphology of Cladosporium carrionii (left) and Fonsecaea pedrosoi (right), the 2 most commonly isolated agents in chromoblastomycosis.

Chromoblastomycosis, tumoral form. Chronic disease led to elephantiasis and involvement of the entire lower limb.

Plaque lesion on the foot. The verrucous aspect of the lesion differentiates it from other infectious dermatoses that may present as a verrucous lesion, namely, cutaneous leishmaniasis, sporotrichosis, cutaneous tuberculosis, and cutaneous mycobacteriosis.

Culture of Fonsecaea pedrosoi on Sabouraud agar. The black velvety colony has the same macroscopic appearance as the colonies of other chromoblastomycosis-causing agents (eg, Cladosporium carrionii, Fonsecaea compacta, Phialophora verrucosa, Rhinocladiella aquaspersa, Exophiala species).

Hematoxylin and eosin–stained section shows typical sclerotic cells inside an abscess. Sclerotic cells present as round, thick-walled, cigar-colored structures.